Skip to main content

Table 2 Response to nab-paclitaxel in the intent-to-treat population

From: A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer

Response

Number of patients

%

 Complete response

0

0

 Partial response

6

19.3

 Stable disease

17

54.8

 Progressive disease

8

25.9

Response Rate

19.3% (95% CI, 9.1%–36.2%) (90% CI, 10.3%–33.2%)

Disease control rate

25

74.1

  1. CI confidence interval